Academic Journal
Rapid Response to Remdesivir in Hospitalised COVID-19 Patients: A Propensity Score Weighted Multicentre Cohort Study
| Title: | Rapid Response to Remdesivir in Hospitalised COVID-19 Patients: A Propensity Score Weighted Multicentre Cohort Study |
|---|---|
| Authors: | Emiel Leegwater, Lisa Dol, Menno R. Benard, Eveline E. Roelofsen, Nathalie M. Delfos, Machteld van der Feltz, Femke P. N. Mollema, Liesbeth B. E. Bosma, Loes E. Visser, Thomas H. Ottens, Nathalie D. van Burgel, Sesmu M. Arbous, Lahssan H. El Bouazzaoui, Rachel Knevel, Rolf H. H. Groenwold, Mark G. J. de Boer, Leo G. Visser, Frits R. Rosendaal, Erik B. Wilms, Cees van Nieuwkoop |
| Source: | Infectious Diseases and Therapy, Vol 12, Iss 10, Pp 2471-2484 (2023) |
| Publisher Information: | Adis, Springer Healthcare, 2023. |
| Publication Year: | 2023 |
| Collection: | LCC:Infectious and parasitic diseases |
| Subject Terms: | Remdesivir, COVID-19, Hospitalized patients, Rapid clinical improvement, Infectious and parasitic diseases, RC109-216 |
| More Details: | Abstract Introduction Remdesivir is a registered treatment for hospitalised patients with COVID-19 that has moderate clinical effectiveness. Anecdotally, some patients’ respiratory insufficiency seemed to recover particularly rapidly after initiation of remdesivir. In this study, we investigated if this rapid improvement was caused by remdesivir, and which patient characteristics might predict a rapid clinical improvement in response to remdesivir. Methods This was a multicentre observational cohort study of hospitalised patients with COVID-19 who required supplemental oxygen and were treated with dexamethasone. Rapid clinical improvement in response to treatment was defined by a reduction of at least 1 L of supplemental oxygen per minute or discharge from the hospital within 72 h after admission. Inverse probability of treatment-weighted logistic regression modelling was used to assess the association between remdesivir and rapid clinical improvement. Secondary endpoints included in-hospital mortality, ICU admission rate and hospitalisation duration. Results Of 871 patients included, 445 were treated with remdesivir. There was no influence of remdesivir on the occurrence of rapid clinical improvement (62% vs 61% OR 1.05, 95% CI 0.79–1.40; p = 0.76). The in-hospital mortality was lower (14.7% vs 19.8% OR 0.70, 95% CI 0.48–1.02; p = 0.06) for the remdesivir-treated patients. Rapid clinical improvement occurred more often in patients with low C-reactive protein (≤ 75 mg/L) and short duration of symptoms prior to hospitalisation ( |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 2193-8229 2193-6382 |
| Relation: | https://doaj.org/toc/2193-8229; https://doaj.org/toc/2193-6382 |
| DOI: | 10.1007/s40121-023-00874-2 |
| Access URL: | https://doaj.org/article/17449ed6f2c14287ad8e56894159692a |
| Accession Number: | edsdoj.17449ed6f2c14287ad8e56894159692a |
| Database: | Directory of Open Access Journals |
| Full text is not displayed to guests. | Login for full access. |
| ISSN: | 21938229 21936382 |
|---|---|
| DOI: | 10.1007/s40121-023-00874-2 |
| Published in: | Infectious Diseases and Therapy |
| Language: | English |